Synaffix announces licensing agreement with CKD Pharm

Published: 6-Feb-2023

Under the terms of the agreement, Synaffix has received an upfront payment and is eligible to receive further milestone payments

Biotech company Synaffix and Chong Kun Dang Pharm (CKD), a pharmaceutical company based in South Korea, have entered a licensing agreement.

The agreement provides CKD a license for global, target-specific rights to Synaffix’s proprietary ADC technology, adding a new ADC drug candidate to CKD’s pipeline. CKD will have access to Synaffix’s ADC technologies, comprising GlycoConnect, HydraSpace and an undisclosed linker-payload from the toxSYN platform. 

Under the terms of the agreement, Synaffix has received an upfront payment and is eligible to receive further milestone payments plus royalties on commercial sales. CKD will be responsible for the research, development, manufacturing and commercialisation of the ADCs. Synaffix will be responsible for the manufacturing of components that are specifically related to its proprietary technologies.

By combining our existing oncology expertise and related technologies with the ADC platform of Synaffix, we have been able to efficiently establish a novel ADC candidate

Peter van de Sande, Chief Executive Officer of Synaffix, said: “Scientific rigor and a growing body of promising underlying data have led us to this exciting moment where we can bring a new ADC into the development pipeline of CKD Pharm.  We value the strong experience of the CKD team within the oncology space and look forward to building on this further as we continue our close and long-standing collaboration aimed at bringing this promising new drug candidate to patients in need.”

Young-Joo, Kim, Chief Executive Officer of CKD Pharm said: “By combining our existing oncology expertise and related technologies with the ADC platform of Synaffix, we have been able to efficiently establish a novel ADC candidate for CKD’s pipeline. CKD’s work is deeply rooted in oncology, and we are committed to improving the quality of life for patients by developing highly targeted novel drugs for the treatment of cancer.”

RM Global Partners LLC and DLA Piper LLP (US) acted as CKD’s advisors for this transaction.

 

 

You may also like